Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

The effect of PARP inhibition on androgen receptor localization and activity in castration resistant prostate cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...

In patients with high PD-L1 expression identified before surgery, clinicians should consider the possibility of lymph node metastasis when determining surgical strategy, including the extent of lymph ...

The study of constructed αROR1‐CAR T cells showed an increase of PD-L1 expression when exposed to elevated pressure, driving resistance to CAR T cell-mediated cytotoxicity. However, the findings also ...

This study was led by Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Chinese Thoracic Oncology Group (CTONG)). In this open-label, phase 2 study (NCT04252365), ...

The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...